Flexipharm Austrading
- Company typePrivate
- Founded2018
- HeadquartersMarkyate, United Kingdom
- Headcount—
- GTM typeB2B
- OfferingServices
Flexipharm Austrading firmographics
Firmographics- Name
- Flexipharm Austrading
- Legal name
- Flexipharm Austrading Limited
- Website
- https://flexipharmaustrading.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Ownership category
- akta.pro rank
Flexipharm Austrading industry classification
Industry- Product category
- Specialty Pharmaceuticals (Injectable Critical Care Medicines)
- NAICS
- Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where Flexipharm Austrading is headquartered
LocationHeadquarters
- HQ city
- Markyate
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Flexipharm Austrading business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Pharmaceutical product sales to NHS hospitals: Flexipharm acquires exclusive distribution rights to novel or better presentations of injectable critical care medicines and supplies them to UK NHS and independent hospitals. The company generates revenue through product sales at prices lower than existing alternatives, targeting minimum 7.5% cost savings versus competitor products. They submit products for inclusion on NHS Framework Agreements for transparent pricing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Methylthioninium Chloride 10mg/ml vials - £150.00 per pack |
| Unit Pricing | Pay-as-you-go | Target pricing for all products - minimum 7.5% cost saving |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels3 records
Flexipharm Austrading product offering
Product offeringCore offering
Flexipharm Austrading is a UK specialty pharmaceutical company that acquires exclusive distribution rights to novel or better presentations of injectable critical care medicines and supplies them to UK NHS and independent hospitals. Its portfolio comprises four injectable critical care medicines (Arsenic Trioxide Phebra, Methylthioninium Chloride, Metaraminol 10mg/ml and Metaraminol 0.5mg/ml) presented in vials rather than ampoules to reduce sharps injuries and consumable costs. Products are manufactured by Australian partner Phebra at an MHRA, EMA and FDA approved facility and distributed via exclusive wholesaler Mawdsleys.
Product overview
Flexipharm Austrading is a specialty pharmaceutical company that supplies generic injectable critical care medicines to UK NHS and independent hospitals. The company focuses on supplying vials (rather than traditional ampoules) of established 'gold standard' medicines that offer improvements in safety, cost, and administration. The product portfolio includes four injectable medicines: Arsenic Trioxide Phebra (for acute promyelocytic leukaemia), Methylthioninium Chloride (for methaemoglobinaemia), and two Metaraminol presentations (10mg/ml and 0.5mg/ml for acute hypotension). All products are supplied in vial format to reduce sharps injuries and eliminate the need for filter straws/needles. The company operates under exclusive distribution agreements with Australian manufacturer Phebra Pty Ltd.
Differentiator
Problem solved
Functional benefit
Products and services
- Arsenic Trioxide Phebra 1mg/ml Concentrate for Solution for Infusion Novel vial presentation of arsenic trioxide concentrate for solution for infusion, indicated for the treatment of low-intermediate risk Acute Promyelocytic Leukaemia (APML). Available in 10ml and 20ml vials, supplied in Type I moulded glass with a protective plastic shrink-wrap sleeve and base cup. Eliminates the need for filter needles or straws and reduces sharps injury risk for NHS specialist pharmacists.
- Methylthioninium Chloride 10mg/ml Sterile Concentrate for Solution for Injection First and only generic licensed vial presentation of methylthioninium chloride, indicated for treatment of medicinal, chemical-induced and genetic methaemoglobinaemia. Priced at £150 per pack, 23% cheaper than the alternative ampoule product at £196.89, with an improved in-use shelf life of up to 24 hours from opening.
- Metaraminol 10mg/ml Solution for Injection/Infusion First user-safety focused vial presentation of Metaraminol 10mg/ml in the UK, indicated for treatment of acute hypotension due to loss of vasoconstrictor tone as may occur during spinal anaesthesia. Typically used to prepare an infusion.
- Metaraminol 0.5mg/ml (5mg in 10ml) Solution for Injection/Infusion First vial presentation of Metaraminol 0.5mg/ml (5mg in 10ml) available in the UK, indicated for treatment of acute hypotension due to loss of vasoconstrictor tone as may occur during spinal anaesthesia. This strength is typically administered as a bolus in the operating theatre.
Quantifiable outcome
- 23% cost savings on Methylthioninium Chloride (£150 vs £196.89 for ampoule alternative)
- +2 more outcomes
Companies that use Flexipharm Austrading
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Flexipharm Austrading technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Flexipharm Austrading partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Phebra Pty LtdcoreExclusive license and distribution agreement with Phebra Pty Ltd, an Australian company that develops, manufactures and supplies high quality and innovative pharmaceuticals for the hospital specialty pharmaceutical market. Phebra has a modern specialist injectable medicines facility approved by MHRA, EMA, and FDA. This partnership has enabled launch of multiple injectable critical care medicines since 2019 including Arsenic Trioxide Phebra (approved May 2019), Methylthioninium Chloride, and Metaraminol products.
- MawdsleyscoreExclusive wholesaler partnership with Mawdsleys for distribution of all products to NHS and independent hospitals. Products including Arsenic Trioxide Phebra and Methylthioninium Chloride are available from Mawdsleys.
Scale indicators8 records
Recent moves6 records
Expansion highlights4 records
Flexipharm Austrading competitors and assessment
Company assessmentOthers
- Phebra Pty Ltd: Australian specialty injectable pharmaceutical manufacturer and Flexipharm's exclusive partner and equity holder. While not a direct competitor, Phebra is the upstream manufacturing partner whose portfolio drives Flexipharm's product roadmap — a critical ecosystem participant.
- Mawdsleys: UK pharmaceutical wholesaler and Flexipharm's exclusive distribution partner. As Flexipharm's wholesaler of record, Mawdsleys is a channel partner rather than competitor, but shares the same NHS-facing specialty pharma distribution ecosystem.
Broad incumbents
- Hikma Pharmaceuticals: Global specialty pharmaceutical company with a substantial hospital injectables franchise serving the UK NHS. Comparable in product category (sterile injectable generics) and customer base (UK hospitals), but at much larger scale and with broader geographic reach.
- Aspen Pharmacare: Global specialty pharmaceutical company with a meaningful hospital injectables portfolio in the UK and Europe. Comparable in therapeutic focus (specialty/hospital injectables) and customer base, but operates as a much larger incumbent across multiple geographies.
- Advanz Pharma (formerly Mercury Pharma): UK-headquartered specialty pharmaceutical company with a significant portfolio of established branded and generic medicines, many for hospital use. Comparable in customer base (NHS hospitals) and specialty-pharma positioning, though much larger and broader in scope.
Direct peers
- Martindale Pharma: UK specialty pharmaceutical company focused on hospital injectable medicines, including critical care products. Comparable to Flexipharm in target market (UK hospitals), product category (injectables), and specialty-pharma distribution model.
- Hameln Pharmaceuticals: European specialty manufacturer of hospital injectable generics. Comparable to Flexipharm in focus on injectable hospital generics, supply to UK/NHS, and product format including ampoules and vials.
- Flynn Pharma: UK-based specialty pharmaceutical company focused on niche hospital and specialty medicines, often via licensing/distribution arrangements. Closely comparable to Flexipharm in business model (exclusive distribution of partner-manufactured products to UK hospitals), therapeutic focus on hospital injectables, and customer base (NHS).
- Ethypharm: European specialty pharmaceutical company with significant hospital injectables portfolio, including critical care products. Comparable in business model (specialty injectable distribution to hospitals), therapeutic areas (critical care), and product-format focus.
Emerging players
- Stragen Pharma: European specialty pharmaceutical company focused on niche injectable medicines for hospitals. Comparable in focus on specialty injectable generics for hospital use, though smaller and more regionally concentrated than Flexipharm's current UK footprint.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Flexipharm Austrading compliance and trust
Trust signalCompliance6 records
Flexipharm Austrading financial estimates
Financial estimateRevenue estimate
Valuation estimate
Flexipharm Austrading leadership team
Management profileNumber of profiles
Profiles1 record
Flexipharm Austrading funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Flexipharm Austrading M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Flexipharm Austrading
What does Flexipharm Austrading do?
Flexipharm Austrading is a UK specialty pharmaceutical company that acquires exclusive distribution rights to novel or better presentations of injectable critical care medicines and supplies them to UK NHS and independent hospitals. Its portfolio comprises four injectable critical care medicines (Arsenic Trioxide Phebra, Methylthioninium Chloride, Metaraminol 10mg/ml and Metaraminol 0.5mg/ml) presented in vials rather than ampoules to reduce sharps injuries and consumable costs. Products are manufactured by Australian partner Phebra at an MHRA, EMA and FDA approved facility and distributed via exclusive wholesaler Mawdsleys.
Is Flexipharm Austrading a public or private company?
Flexipharm Austrading is a private company. It is classified as corporate owned and is currently operating.
When was Flexipharm Austrading founded?
Flexipharm Austrading was founded in 2018.
Where is Flexipharm Austrading based?
Flexipharm Austrading is headquartered in Markyate, United Kingdom, in the Europe region.
How does Flexipharm Austrading make money?
One revenue line is on record: pharmaceutical product sales to NHS hospitals.
Who are Flexipharm Austrading's main competitors?
Others on record are Phebra Pty Ltd and Mawdsleys. Broad incumbents are Hikma Pharmaceuticals, Aspen Pharmacare and Advanz Pharma (formerly Mercury Pharma). Direct peers are Martindale Pharma, Hameln Pharmaceuticals, Flynn Pharma and Ethypharm. Stragen Pharma is listed as an emerging player.
Does Flexipharm Austrading have an API?
No public API is recorded for Flexipharm Austrading.
What industry is Flexipharm Austrading in?
Flexipharm Austrading's product category is Specialty Pharmaceuticals (Injectable Critical Care Medicines). Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 3391 and its SIC code is 5122.